LT4482B - Novel 1-ar(alk)yl-imidazolin-2-ones containing a disubstituted amine radical in the 4th position, having an anticonvulsive effect, and process for their production - Google Patents

Novel 1-ar(alk)yl-imidazolin-2-ones containing a disubstituted amine radical in the 4th position, having an anticonvulsive effect, and process for their production Download PDF

Info

Publication number
LT4482B
LT4482B LT98-047A LT98047A LT4482B LT 4482 B LT4482 B LT 4482B LT 98047 A LT98047 A LT 98047A LT 4482 B LT4482 B LT 4482B
Authority
LT
Lithuania
Prior art keywords
morpholinimidazolin
compounds
imidazolin
alkyl
general formula
Prior art date
Application number
LT98-047A
Other languages
Lithuanian (lt)
Other versions
LT98047A (en
Inventor
Hans-Joachim Lankau
Manfred Menzer
Klaus Unverferth
Karl Gewald
Harry Schafer
Original Assignee
Arzneimittelwerk Dresden Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7771261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4482(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arzneimittelwerk Dresden Gmbh filed Critical Arzneimittelwerk Dresden Gmbh
Publication of LT98047A publication Critical patent/LT98047A/en
Publication of LT4482B publication Critical patent/LT4482B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88Nitrogen atoms, e.g. allantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds with an anti-convulsive effect of general formula (1) in which X = hydrogen, C1-C4 alkyl, C1-C4 alkoxy, trifluoromethyl, halogen and R<1> or R<2> = C1-C4 alkyl, cycloalkyl or heteroalkyl.

Description

kurioje: X yra vandenilis, CpC^alkilas, CpC^alkoksilas, trifluormetilas arba halogenas: R1 ir R2 yra C)-C4-alkilas, cikloalkilas arba heteroalkilas.wherein: X is hydrogen, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl or halogen: R 1 and R 2 are C 1 -C 4 alkyl, cycloalkyl or heteroalkyl.

Šis išradimas yra susijęs su 1-aril(alkil)imidazolin-2-onais, turinčiais dipakeistą aminogrupę 4 padėtyje, su jų gavimo būdais ir jų panaudojimu kaip įo farmacinių priemonių centrinės nervų sistemos susirgimų, konkrečiai, įvairių formų epilepsijos, gydymui.The present invention relates to 1-aryl (alkyl) imidazolin-2-ones having a disubstituted amino group at the 4-position, processes for their preparation and their use as pharmaceuticals for the treatment of central nervous system disorders, in particular various forms of epilepsy.

Pagal žinomą technikos lygį 1-aril(alkil)imidazolin-2-onus, turinčius nepakeistą amino arba metilaminogrupę 4 padėtyje, gauna aril(alkil)aminoacetamidams reaguojant su bromcianu. N-alkilinant tokiu būdu gautus 4-amino-1-aril(alkil)imidazolin-2-onus, gauna 3-alkil- arba 1-iminoalkil-3alkil-1 -aril(alkil)imidazolin-2-onus, be to aminogrupe 4 padėtyje tautomerizuojasi j iminogrupę. To pasėkoje tolesnis N-alkilinimas, siekiant gauti bendros 1 formulės junginius, yra neįmanomas, ir ryšium su tuo atitinkančių šį išradimą junginių tokiu būdu gauti negalima (JAV patentas Nr. 4044021; Vokietijos patentas Nr.In the prior art, 1-aryl (alkyl) imidazolin-2-ones having an unsubstituted amino or methylamino group at the 4-position are obtained by reacting aryl (alkyl) aminoacetamides with bromocyano. N-alkylating the 4-amino-1-aryl (alkyl) imidazolin-2-one thus obtained gives 3-alkyl- or 1-iminoalkyl-3alkyl-1-aryl (alkyl) imidazolin-2-one, in addition to amino group 4. position tautomerizes to the iminogroup. As a result, further N-alkylation to obtain compounds of general formula 1 is not possible, and the corresponding compounds of the present invention cannot be obtained in this way (U.S. Patent No. 4,404,402;

2251354).2251354).

-Aril(alkil)imidazolin-2-onai, turintys dipakeistą aminogrupę 4 padėtyje, iki šiol nėra aprašyti.-Aryl (alkyl) imidazolin-2-ones having a substituted amino group at the 4-position are not yet described.

Žinoma daugybė junginių, pasižyminčių antispazminiu veikimu. Tačiau dar ir dabar ne visų epileptinių sindromų gydymas duoda patenkinamus rezultatus.Numerous compounds with antispasmodic activity are known. However, the treatment of all epileptic syndromes is still not satisfactory.

Tokiu būdu, šio išradimo tikslas yra naujų junginių, pasižyminčių palankiomis farmakologinėmis savybėmis, kuriuos galima naudoti, pavyzdžiui, kaip farmacinius preparatus, ir pasižyminčių antispazminiu veikimu, pateikimas.Thus, it is an object of the present invention to provide novel compounds having favorable pharmacological properties which can be used, for example, as pharmaceutical preparations, and which possess antispasmodic activity.

Pagal šj išradimą tie nauji junginiai yra 1-ari(alkil)imidazolin-2-onai, kurių bendra formulė yra 1:According to the present invention, those novel compounds are 1-ary (alkyl) imidazolin-2-ones of the general formula 1:

n = O, 1; m = 0,1, 2, 3, 4, 5; kurioje:n = 0.1; m = 0.1, 2, 3, 4, 5; where:

X yra vandenilis, CrCA-alkilas, CrC^alkoksilas, trifluormetilas arba halogenas;X is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, trifluoromethyl or halogen;

R1 ir R2 yra CpCA-alkilas, eikloalkilas arba heteroalkilas, kur alkilo grupė pasirinktinai apima 5-7 anglies atomus, arbaR 1 and R 2 are CpCA-alkyl, eicycloalkyl or heteroalkyl, wherein the alkyl group optionally contains 5 to 7 carbon atoms, or

R1 ir R2 kartu sudaro alkileno grupę, turinčią 2-6 anglies atomus, kur -CH2io grupė gali būti pakeista deguonim, azotu arba siera.R 1 and R 2 together form an alkylene group having from 2 to 6 carbon atoms, wherein the -CH 2 io group may be replaced by oxygen, nitrogen or sulfur.

CH2 grupių skaičius lygus arba 0 (1-arilimidazolin-2-onai), arba 1 (1arilalkilimidazolin-2-onai).The number of CH 2 groups is equal to either 0 (1-arylimidazolin-2-one) or 1 (1-arylalkylimidazolin-2-one).

Junginių, turinčių bendrą formulę 1, pavyzdžiai yra šie: 1-fenil-4-morfolinimidazolin-2-onasExamples of compounds of general formula 1 are: 1-phenyl-4-morpholinimidazolin-2-one

1-(4-metoksi)-4-piperidinimidazolin-2-onas1- (4-Methoxy) -4-piperidinimidazolin-2-one

1-(4-chlorfenil)-4-morfolinimidazolin-2-onas 1-(4-chlorfenil)-piperidinimidazolin-2-onas 1-(4-chlorfenil)-4-dimetilaminoimidazolin-2-onas 1-(4-bromfenil)-4-morfolinimidazolin-2-onas1- (4-Chlorophenyl) -4-morpholinimidazolin-2-one 1- (4-chlorophenyl) -piperidinimidazolin-2-one 1- (4-chlorophenyl) -4-dimethylaminoimidazolin-2-one 1- (4-bromophenyl) -4-morpholinimidazolin-2-one

1 -(3-chlorfenil)-4-morfolinimidazolin-2-onas1- (3-chlorophenyl) -4-morpholinimidazolin-2-one

1-(4-chlorfenil)-4-heksametileniminoimidazolin-2-onas1- (4-Chlorophenyl) -4-hexamethyleniminoimidazolin-2-one

1-(4-chlorfenil)-4-(4-metilpiperazino)imidazolin-2-onas1- (4-Chlorophenyl) -4- (4-methylpiperazino) imidazolin-2-one

1-(4-metilfenil)-4-morfolinimidazolin-2-onas1- (4-Methylphenyl) -4-morpholinimidazolin-2-one

1-(4-chlorfenil)-4-(cikloheksilmeti!amino)imidazolin-2-onas1- (4-Chlorophenyl) -4- (cyclohexylmethylamino) imidazolin-2-one

1 -(4-fluorfenil)-4-morfolinimidazolin-2-onas1- (4-Fluorophenyl) -4-morpholinimidazolin-2-one

1-benzil-4-morfolinimidazolin-2-onas.1-Benzyl-4-morpholinimidazolin-2-one.

Pagal šį išradimą bendrą formulę 1 turintys junginiai gali būti gauti nauju būdu, reaguojant bendros formulės 2 junginiamsThe compounds of the general formula 1 according to the present invention can be obtained in a novel manner by reacting the compounds of the general formula 2

H n = 0,1; m = 0,1,2, 3, 4, 5;H n = 0.1; m = 0,1,2,3,4,5;

kurioje X yra vandenilis, CrC^alkilas, Ci-C4-alkoksilas, trifluormetilas arba halogenas;wherein X is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, trifluoromethyl or halogen;

su antriniu aminu.with a secondary amine.

Alternatyviai, formulę 1 turintys junginiai gali būti gauti tirpiklyje arba antrinio amijo pertekliuje nuo 50 iki 160 °C temperatūroje. Tinkami tirpikliai, kuriems teikiama pirmenybė, yra aromatiniai angliavandeniliai, tokie kaip benzenas, toluenas, chlorbenzenas arba dichlorbenzenas.Alternatively, the compounds of Formula 1 may be obtained in a solvent or in an excess of secondary amide at 50 to 160 ° C. Suitable preferred solvents are aromatic hydrocarbons such as benzene, toluene, chlorobenzene or dichlorobenzene.

Geriausia, kai reakcija vyksta esant medžiagų, surišančių vandenį, pavyzdžiui, esant ceoiitų arba natrio sulfato. Reakciją galima pagreitinti pridedant įprastų kondensacijos katalizatorių, pavyzdžiui, 4-toluensulforūgšties.The reaction is preferably carried out in the presence of water-binding substances such as zeolites or sodium sulfate. The reaction can be accelerated by the addition of conventional condensation catalysts such as 4-toluenesulfonic acid.

Šio išradimo junginiai tinka farmacinių kompozicijų sudarymui. J farmacinių kompozicijų sudėtį gali įeiti vienas ar daugiau šio išradimo junginių. Farmacinių preparatų gavimui gali būti naudojami įprastiniai farmaciniai užpildai ir pagalbinės medžiagos.The compounds of the present invention are suitable for the preparation of pharmaceutical compositions. The pharmaceutical compositions may contain one or more compounds of the present invention. Conventional pharmaceutical excipients and excipients may be used in the preparation of pharmaceutical preparations.

Vaistai gali būti įvedami parenteraliai (pavyzdžiui, į veną, į raumenis arba po oda) arba peroraliai.The drugs may be administered parenterally (for example, intravenously, intramuscularly or subcutaneously) or orally.

Vaisto formos gali būti paruoštos žinomais ir plačiai paplitusiais farmacijoje . būdais.The formulations may be formulated according to known and widely used pharmaceutical formulations. ways.

Šio išradimo junginiai pasižymi stipriu antispazminiu veikimu.The compounds of the present invention exhibit potent antispasmodic activity.

Šių preparatų antispazminis veikimas buvo tikrinamas in vivo įvedus pelėms intraperitoniškai arba žiurkėms peroraliai, pagal tarptautinių standartų reikalavimus (Pharmac. VVeekblad, 2nd ed., 14, 132 (1992) ir Antiepileptic drugs, 3rd ed., Raven press, New York (1989)) (1 lentelė).The antispasmodic activity of these preparations has been tested by in vivo administration to mice intraperitoneally or orally in rats according to international standards (Pharmac. Weekblad, 2nd ed., 14, 132 (1992) and Antiepileptic drugs, 3rd ed., Raven press, New York (1989). ) (Table 1).

Pavyzdžiui, junginio 2 (1-(4-chlorfenil)-4-morfolinimidazolin-2-onas) efektyvi dozė ED50 (peroraliai) maksimalaus elektrošoko žiurkėms atveju yra 21 mg/kg, ED50, įvedant pentetrazolą po oda yra 16 mg/kg ir NT50 neurotoksiškumo bandymuose yra >400 mg/kg. Palyginimui, žinomi priešepileptiniai vaistai yra aktyvūs arba maksimalaus elektrošoko modelyje, arba įvedus pentetrazolą, arba, esant santykinai dideliems aktyvumams, jie rodo pernelyg didelį neurotoksiškumą įvedus pentetrazolą.For example, the effective dose of compound 2 (1- (4-chlorophenyl) -4-morpholinimidazolin-2-one) for ED 50 (oral) at maximal electroshock rats is 21 mg / kg, ED 50 for subcutaneous administration of pentetrazole is 16 mg / kg. and NT 50 in neurotoxicity assays is> 400 mg / kg. In comparison, known antiepileptic drugs are active either in the maximal electroshock model, either after administration of pentetrazole or, at relatively high activities, they exhibit excessive neurotoxicity after administration of pentetrazole.

LENTELĖTABLE

Junginių Nr., pagal pavyzdžius11 Compound Nos. By Examples 11 log P21 log P 21 Tyrimas31 study 31 Dozė41 Dose 41 Poveikis51 Impact 51 1 1 0,64 0.64 MES PTZ MES PTZ 100 100 100 100 30 30 30th 30th 2 2 1,48 1.48 MES PTZ MES PTZ 300 30 300 30th 30 70 30th 70 3 3 2,29 2.29 MES PTZ MES PTZ 100 100 100 100 100 100 100 100 4 4 0,48 0.48 MES PTZ MES PTZ 300 300 300 300 30 30 30th 30th 5 5 2,17 2.17 MES PTZ MES PTZ 300 300 300 300 100 100 100 100 6 6th 1,61 1.61 MES PTZ MES PTZ 300 100 300 100 100 20 100 20th 7 7th 1,53 1.53 MES PTZ MES PTZ 300 100 300 100 100 100 100 100 8 8th 1,45 1.45 MES PTZ MES PTZ 300 100 300 100 30 100 30th 100 9 9th 0,97 0.97 MES PTZ MES PTZ 100 100 100 100 30 100 30th 100 10 10th 1,28 1.28 MES PTZ MES PTZ '300 300 '300 300 10 70 10th 70 1111th 2,56 2.56 MES · PTZ MES · PTZ 300 300 300 300 100 40 100 40

Palyginimo medžiaga Comparison Material Tyrimas31 study 31 Dozė41 Dose 41 Poveikis51 Impact 51 Karbamazepinas Carbamazepine MES MES 100 100 100 100 PTZ PTZ 100 100 0 0 Valproatas Valproate MES MES 100 100 0 0 PTZ PTZ 100 100 30 30th

Pastabos:Notes:

1) Dėl junginių numeravimo žiūr. pavyzdžius.1) For compound numbering, see marg. examples.

2) Pasiskirstymo koeficientas sistemoje oktanolis-vanduo.2) Partition coefficient in octanol-water system.

3) MES - maksimalus elektrošokas, PTZ - pentetrazolis, įvedimas po oda.3) MES - maximum electroshock, PTZ - pentetrazole, subcutaneous administration.

4) mg/kg4) mg / kg

5) apsaugotų gyvuliukų %.5)% of protected animals.

Naujų, turinčių 1 formulę junginių gavimas detaliau iliustruojamas darbiniais pavyzdžiais.The preparation of novel compounds of formula 1 is further illustrated by working examples.

PAVYZDŽIAIEXAMPLES

Bendra 1 formulės junginių pagal 1 lentelę gavimo procedūra, 1-11 pavyzdžiaiGeneral procedure for the preparation of compounds of formula 1 according to Table 1, Examples 1-11

A variantas.Option A.

0,05 molio 1-arilimidazolin-2,4-diono, turinčio bendrą 2 formulę (n=0), 200mg 4-toluensulforūgšties pridėjo j 100 ml tinkamo antrinio amino. Po to mišinį virino kolboje su grįžtamu šaldytuvu Soksleto ekstraktoriuje, kurio ekstrakcinė kapsulė užpildyta 25 g kietos medžiagos, surišančios vandenį (tinka, pavyzdžiui, natrio sulfatas, magnio sulfatas, NaOH, KOH, ceolitai). Po 8-30 vai.karštą mišinį nufiltravo ir distiliavo rotoriniame garintuve iki maždaug pusės tūrio. Skaidresnį tirpalą atšaldė ledo vonioje, o susidariusią tirštą kristalų vandeninę suspensiją atskyrė nuo amino. Pradinę medžiagą, . esančią nevalytame produkte, išekstrahavo 50 ml karšto acetono. Produktą perkristalino iš n-propanolio.0.05 mol of 1-arylimidazoline-2,4-dione of general formula 2 (n = 0), 200 mg of 4-toluenesulphonic acid were added per 100 ml of the appropriate secondary amine. The mixture was then refluxed in a Soxhlet extractor containing 25 g of water-soluble solids (suitable, for example, sodium sulfate, magnesium sulfate, NaOH, KOH, zeolites). After 8-30 hours, the hot mixture was filtered and distilled in a rotary evaporator to about half volume. The clear solution was cooled in an ice bath and the resulting thick crystal aqueous suspension was separated from the amine. Starting material, -. Extract 50 ml of hot acetone in the crude product. The product was recrystallized from n-propanol.

Iš atskirto amino galima išskirti iki 0,02 mol nesureagavusio 1ariliniidazolin-2,4-diono.Up to 0.02 mol of unreacted 1aryl imidazoline-2,4-dione can be isolated from the isolated amine.

B variantas.Option B.

0,05 mol 1-arilalkilimidazolin-2,4-dionas, turintis bendrą 2 formulę (n=1) reaguoja su antriniu aminu, kaip aprašyta A variante. Po 8-30 vai. karštą tirpalą nufiltruoja ir koncentruoja iki sausos liekanos rotoriniame garintuve. Į liekaną prideda 50 ml metilenchlorido ir 50 ml 2 N HCI. Organinę fazę atskiria, vandeninę fazę papildomai du kartus ekstrahuoja metilenchloridu. Atskirtą vandeninę fazę pašarmina, pridėdami 50 ml 10 % NaOH, ir 1,4-amino-1-arilalkilimidazolin-2-oną išekstrahuoja 100 ml metilenchlorido. Ekstraktus džiovina natrio sulfatu. Nudistiliavus metilenchloridą, nevalytą produktą perkristalina iš etanolio arba acetono.0.05 mol of 1-arylalkylimidazoline-2,4-dione of general formula 2 (n = 1) is reacted with a secondary amine as described in variant A. After 8-30 or. the hot solution is filtered and concentrated to dryness in a rotary evaporator. To the residue are added 50 mL of methylene chloride and 50 mL of 2N HCl. The organic phase is separated off and the aqueous phase is further extracted twice with methylene chloride. The separated aqueous phase is made alkaline by the addition of 50 ml of 10% NaOH and the 1,4-amino-1-arylalkylimidazolin-2-one is extracted with 100 ml of methylene chloride. The extracts are dried over sodium sulfate. After distillation with methylene chloride, the crude product is recrystallized from ethanol or acetone.

C variantas.Option C.

0,05 mol 1 -aril(alkil)imidazolin-2,4-diono, turinčio bendrą 2 formulę, reaguoja su 100 ml dimetilamoniodimetilkarbamato, kaip aprašyta A ir B variantuose. Po 40 vai. mišinį apdoroja pagal A arba B variantą.0.05 mol of 1-aryl (alkyl) imidazoline-2,4-dione of general formula 2 is reacted with 100 ml of dimethylammoniodimethylcarbamate as described in variants A and B. After 40 or so. the mixture is treated according to variant A or B.

LENTELĖTABLE

Pvz. Nr. For example, No. R1 R 1 R2 R 2 Varian- tas Variant- it Reakcijos truk- mė(val) Reaction time- mh ~ O _j ~ O _j Išeiga (%) Yield (%) 1 1 \_/ \ _ / A A 15 15th 248 248 421) 42 1) 2 2 -O-ci -O- ci _n _n A A 15 15th 266 266 75n 75 n 3 3 ~CGci ~ CG ci -o -o A A 20 20th .248 .248 601) 60 1) 4 4 c H t —fr. ~2>- c H t —fr. ~ 2> -O -O B B 15 15th 158 158 48 48 5 5 - n( \ —CH J - n (\ —CH J A A 12 12th 254 254 681) 68 1) 6 6th —ę^~c'—One ^ ~ c ' C H , -N ZZ 3 H jCH, -N ZZ 3 H j C C 40 40 292 292 13 13th 7 7th -O-0CH3-O- OCH 3 -O -O A A 30 30th 190 190 521) 52 1) 8 8th -O -O A A 15 15th 268 268 65n 65 n 9 9th ~OF ~ O F -O -O A A 18 18th 255 255 541'54 1 ' 10 10th -O -O B B 30 30th 237 237 27 27th 11 11th GGci GG ci -O -O A A 8 8th 216 216 881) 88 1)

1) įvertinant išeigą, įskaityta išskirta pradinė medžiaga.(1) isolated starting material is included in the yield assessment.

Claims (7)

IŠRADIMO APIBRĖŽTISDEFINITION OF INVENTION 5 1. Nauji junginiai, turintys bendrą formulę 1 n = 0, 1 m = 0, 1, 2, 3, 4, 5 kurioje: X yra vandenilis, Ci-C4-alkilas, CrC4-alkoksilas, trifluormetilas arba io halogenas;5 1. Novel compounds of general formula 1 n = 0, 1, m = 0, 1, 2, 3, 4, 5, wherein X is hydrogen, Ci-C 4 -alkyl, CRC 4-alkoxy, trifluoromethyl or halogen io ; R1 ir R2 yra Ci-C4-alkilas, cikloalkilas arba heteroalkilas, kur alkilo grupė pasirinktinai apima 5-7 anglies atomus, arbaR 1 and R 2 are C 1 -C 4 alkyl, cycloalkyl or heteroalkyl wherein the alkyl group optionally contains 5 to 7 carbon atoms, or R1 ir R2 kartu sudaro alkileno grupę, turinčią 2-6 anglies atomus, kur -CH215 grupė gali būti pakeista deguonim, azotu arba siera.R 1 and R 2 together form an alkylene group having from 2 to 6 carbon atoms, wherein the -CH 2 group may be replaced by oxygen, nitrogen or sulfur. 2. Junginiai pagal 1 punktą, besiskiriantys tuo, kad jie yra 1-fenil-4-morfolinimidazolin-2-onas 1 -(4-metoksi)-4-piperidinimidazolin-2-onasCompounds according to claim 1, characterized in that they are 1-phenyl-4-morpholinimidazolin-2-one 1- (4-methoxy) -4-piperidinimidazolin-2-one 20 1 -(4-chlorfenil)-4-morfolinimidazolin-2-onas20 1- (4-Chlorophenyl) -4-morpholinimidazolin-2-one 1-(4-chlorfenil)-piperidinimidazolin-2-onas 1-(4-chlorfenil)-4-dimetilaminoimidazolin-2-onas 1-(4-bromfenil)-4-morfolinimidazolin-2-onas 1-(3-chlorfenil)-4-morfolinimidazolin-2-onas1- (4-Chloro-phenyl) -piperidinimidazolin-2-one 1- (4-chloro-phenyl) -4-dimethylamino-imidazolin-2-one 1- (4-bromo-phenyl) -4-morpholinimidazolin-2-one 1- (3-chloro-phenyl) -4-morpholinimidazolin-2-one 25 1 -(4-chlorfenil)-4-heksametileniminoimidazolin-2-onas1- (4-Chlorophenyl) -4-hexamethyleniminoimidazolin-2-one 1-(4-chlorfenil)-4-(4-metilpiperazino)imidazolin-2-onas 1-(4-metilfenil)-4-morfolinimidazolin-2-onas 1-(4-chlorfenil)-4-(cikloheksilmetilamino)imidazolin-2-onas 1-(4-fluorfenil)-4-morfolinimidazolin-2-onas1- (4-Chlorophenyl) -4- (4-methylpiperazino) imidazolin-2-one 1- (4-methylphenyl) -4-morpholinimidazolin-2-one 1- (4-chlorophenyl) -4- (cyclohexylmethylamino) imidazolin- 2-one 1- (4-fluorophenyl) -4-morpholinimidazolin-2-one 1-(4-fluorfenil)-4-morfoIinimidazolin-2-onas1- (4-Fluorophenyl) -4-morpholinimidazolin-2-one 1-benzil-4-morfolinimidazolin-2-onas.1-Benzyl-4-morpholinimidazolin-2-one. 3. Junginių, turinčių bendrą 1 formulę, gavimo būdas, besiskiriantis tuo, kad junginiai, turintys bendrą formulę 23. A process for the preparation of compounds of general formula 1, characterized in that the compounds of general formula 2 H kurioje: X yra vandenilis, CrC4-alkilas, Ci-C4-alkoksilas, trifluormetilas arba halogenas, reaguoja su antriniu aminu HNR1R2 50-160 °C temperatūrų intervale, ir R1 ir R2 yra tokie, kaip nurodyta aukščiau.H wherein: X is hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxyl, trifluoromethyl or halogen, reacts with the secondary amine HNR 1 R 2 in the range of 50-160 ° C, and R 1 and R 2 are as defined above. 4. Farmaciniai preparatai, besiskiriantys tuo, kad turi kaip aktyvią medžiagą bent jau vieną junginį, kurio bendra formulė 1, ir, pasirinktinai, farmacinius užpildus ir pagalbines medžiagas.Pharmaceutical preparations, characterized in that they contain as active ingredient at least one compound of the general formula 1 and, optionally, pharmaceutical excipients and excipients. 5. Farmaciniai preparatai pagal 4 punktą, besiskiriantys tuo, kad turi kaip aktyvią medžiagą bent jau vieną junginį pagal 2 punktą.Pharmaceutical preparations according to claim 4, characterized in that they contain, as active ingredient, at least one compound according to claim 2. 6. Junginių, turinčių bendrą formulę 1, panaudojimas vaistinių preparatų, skirtų epileptinių sindromų gydymui, gamyboje.Use of compounds of general formula 1 in the manufacture of a medicament for the treatment of epileptic syndromes. 7. Junginių pagal 2 punktą panaudojimas vaistinių preparatų, skirtų epileptinių sindromų gydymui, gamyboje.Use of compounds according to claim 2 for the manufacture of a medicament for the treatment of epileptic syndromes.
LT98-047A 1995-09-05 1998-04-03 Novel 1-ar(alk)yl-imidazolin-2-ones containing a disubstituted amine radical in the 4th position, having an anticonvulsive effect, and process for their production LT4482B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19532668A DE19532668A1 (en) 1995-09-05 1995-09-05 Novel, anticonvulsant 1-ar (alk) yl-imidazolin-2-ones which contain a disubstituted amine radical in the 4-position, and process for their preparation

Publications (2)

Publication Number Publication Date
LT98047A LT98047A (en) 1998-10-26
LT4482B true LT4482B (en) 1999-03-25

Family

ID=7771261

Family Applications (1)

Application Number Title Priority Date Filing Date
LT98-047A LT4482B (en) 1995-09-05 1998-04-03 Novel 1-ar(alk)yl-imidazolin-2-ones containing a disubstituted amine radical in the 4th position, having an anticonvulsive effect, and process for their production

Country Status (32)

Country Link
EP (1) EP0863880B1 (en)
JP (1) JP4030578B2 (en)
CN (1) CN1103762C (en)
AR (1) AR003502A1 (en)
AT (1) ATE254606T1 (en)
AU (1) AU700602B2 (en)
BG (1) BG63917B1 (en)
BR (1) BR9610359A (en)
CA (1) CA2184871C (en)
CZ (1) CZ291839B6 (en)
DE (2) DE19532668A1 (en)
DK (1) DK0863880T3 (en)
EA (1) EA000535B1 (en)
EE (1) EE03562B1 (en)
ES (1) ES2208758T3 (en)
FR (1) FR13C0049I2 (en)
GE (1) GEP20022652B (en)
HK (1) HK1015776A1 (en)
HU (1) HU225956B1 (en)
IL (1) IL123333A (en)
LT (1) LT4482B (en)
LU (1) LU92263I2 (en)
NO (1) NO313829B1 (en)
NZ (1) NZ315624A (en)
PL (1) PL188287B1 (en)
PT (1) PT863880E (en)
SK (1) SK284868B6 (en)
TR (1) TR199800476T1 (en)
TW (1) TW422838B (en)
UA (1) UA46790C2 (en)
WO (1) WO1997009314A1 (en)
ZA (1) ZA967014B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19721580A1 (en) * 1997-05-23 1998-11-26 Dresden Arzneimittel Use of 1-ar (alk) yl-imidazolin-2-one for the treatment of anxiety and tension
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
CN101254189A (en) * 2003-07-11 2008-09-03 埃尔比昂股份公司 Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
EP2093218A1 (en) * 2008-02-22 2009-08-26 Ruggero Fariello Arylalkyl substituted imidazolidinones
BR112014003117A2 (en) 2011-08-12 2017-06-13 Boehringer Ingelheim Vetmedica Gmbh funny (if) current inhibitors for use in a method of treatment and prevention of feline heart failure
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
IT202100000782A1 (en) 2021-01-18 2022-07-18 Procos Spa PROCESS FOR THE SYNTHESIS OF IMEPITOIN

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2251354A1 (en) 1971-10-21 1973-04-26 American Cyanamid Co NEW DIURETICA AND AGENTS FOR TREATMENT OF HYPERAL DOSTERONISM
US4044021A (en) 1971-10-21 1977-08-23 American Cyanamid Company Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932452A (en) * 1975-02-07 1976-01-13 Morton-Norwich Products, Inc. 1-Arylmethyl-2-imidazolidinones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2251354A1 (en) 1971-10-21 1973-04-26 American Cyanamid Co NEW DIURETICA AND AGENTS FOR TREATMENT OF HYPERAL DOSTERONISM
US4044021A (en) 1971-10-21 1977-08-23 American Cyanamid Company Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism

Also Published As

Publication number Publication date
BG102287A (en) 1998-09-30
NO980906L (en) 1998-03-02
NO980906D0 (en) 1998-03-02
EP0863880A1 (en) 1998-09-16
JP4030578B2 (en) 2008-01-09
HK1015776A1 (en) 1999-10-22
HUP9802941A3 (en) 1999-10-28
EE9800063A (en) 1998-08-17
FR13C0049I2 (en) 2014-03-28
ATE254606T1 (en) 2003-12-15
FR13C0049I1 (en) 2013-09-27
DE59610827D1 (en) 2003-12-24
BR9610359A (en) 1999-07-06
MX9801742A (en) 1998-08-30
NO313829B1 (en) 2002-12-09
JPH11512101A (en) 1999-10-19
DE19532668A1 (en) 1997-03-06
CN1103762C (en) 2003-03-26
PL325413A1 (en) 1998-07-20
EA199800271A1 (en) 1998-10-29
LT98047A (en) 1998-10-26
HU225956B1 (en) 2008-01-28
HUP9802941A2 (en) 1999-09-28
DK0863880T3 (en) 2004-03-22
GEP20022652B (en) 2002-03-25
UA46790C2 (en) 2002-06-17
CZ291839B6 (en) 2003-06-18
AR003502A1 (en) 1998-08-05
CN1200728A (en) 1998-12-02
SK284868B6 (en) 2006-01-05
LU92263I2 (en) 2013-10-07
AU6737596A (en) 1997-03-27
TR199800476T1 (en) 1998-06-22
BG63917B1 (en) 2003-06-30
SK21698A3 (en) 1998-10-07
EP0863880B1 (en) 2003-11-19
EE03562B1 (en) 2001-12-17
WO1997009314A1 (en) 1997-03-13
CA2184871C (en) 2001-08-21
IL123333A0 (en) 1998-09-24
ES2208758T3 (en) 2004-06-16
NZ315624A (en) 1998-11-25
IL123333A (en) 2001-10-31
TW422838B (en) 2001-02-21
EA000535B1 (en) 1999-10-28
PL188287B1 (en) 2005-01-31
CZ66198A3 (en) 1998-07-15
AU700602B2 (en) 1999-01-07
CA2184871A1 (en) 1997-03-06
PT863880E (en) 2004-04-30
ZA967014B (en) 1997-08-18

Similar Documents

Publication Publication Date Title
US5236957A (en) N-phenylalkyl substituted α-amino carboxamide derivatives and process for their preparation
US4400394A (en) Benzylidene derivatives
FI62821B (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC THERAPEUTIC HYDROXYSYROR
EP0734379B1 (en) 2-arylalkenyl-azacycloalkane derivatives as sigma receptor ligands, preparation method therefor and therapeutical use thereof
FI69836B (en) PROCEDURE FOR THE FRAMEWORK OF THERAPEUTIC MEDICINAL PRODUCTS 4-PHENYL-1,3-BENZODIAZEPINDERIVAT
PL194745B1 (en) Substituted compounds of 2-benzylamino-2-phenyl acetamide, pharmaceutical composition containing same and application thereof
LT4482B (en) Novel 1-ar(alk)yl-imidazolin-2-ones containing a disubstituted amine radical in the 4th position, having an anticonvulsive effect, and process for their production
IE55872B1 (en) Derivatives of omega-amino acids,the preparation and utilisation thereof,and the compositions containing these derivatives
HU178652B (en) Process for producing pharmaceutically active 2-bracket-amino-butoxy-bracket closed stylbenes
Pavia et al. N, N-Disubstituted 6-alkoxy-2-pyridinamines as anticonvulsant agents
EP0775113B1 (en) N-substituted azabicycloheptane derivatives useful as neuroleptics
EP0475214B1 (en) Caffeic acid derivatives and pharmaceutical compositions containing the same
KR910003711B1 (en) Process for preparing 2-(n-pyrrolidino)-3-isobutoxy-n-substituted phenyl-n-benzylpropylamines
HU190710B (en) Process for preparing 2-/4-piperazinyl/-4-phenyl-quinazoline derivatives
AU611978B2 (en) Araliphatic oxo(hydroxy) amines
SU906366A3 (en) Method for preparing hydrochloride of n-alkyl derivatives of 1-phenyl-2-amino-1,3-propanediol
FI60863C (en) FOERFARANDE FOER FRAMSTAELLNING AV NYA BENTSHYDRYLOXIALKYLAMINDERIVAT MED FOERLAENGD ANTIHISTAMINEFFEKT
FR2507180A1 (en) NOVEL PHENYLALKYLAMINES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINES
US3963748A (en) 1-Phenyl-3-azacarbocyclic-ureas
LT4457B (en) Novel imidazoline-2,4-diones with an ortho-substituted ar(alk)yl radical in position 1, having an anti-convulsive effect, and process for their production
EP0663395A1 (en) 3-(phenylalkylaminoalkyloxy)-5-phenylpyrazole derivatives, process and intermediates for their preparation and their use as cardiac rhythm reduction agent
US4026938A (en) 1-Phenyl-3-azacarbocyclic-ureas
US4052382A (en) 1-phenyl-3-azacarbocyclic-ureas
HU191585B (en) Process for producing tetramethyl-proline-3-carboxamide derivatives and new cardiotherapeutic compositions containing them
DD301657A9 (en) PROCESS FOR THE PREPARATION OF INTERMEDIATE PRODUCTS FOR BIS (BENZYLPYRROLIDIN) DOPANINE AGONISTS

Legal Events

Date Code Title Description
PC9A Transfer of patents

Owner name: ELBION AG, DE

Effective date: 20041130

PD9A Change of patent owner

Owner name: ELBION GMBH, , , DE

Effective date: 20071122

TC9A Change of representative

Owner name: ELBION GMBH, , , DE

MK9A Expiry of a patent

Effective date: 20160726